Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
ASSETS
Cash and cash equivalents	$ 84,228	$ 66,654
Accounts receivable, net of allowance of $1,169 and $116 at December 31, 2012 and 2011, respectively	38,109	38,465	[1]
Inventories	10,424	11,141	[1]
Restricted cash and investments	2,759
Prepaid expenses and other current assets	1,809	1,646
Deferred tax assets		1,788
Total current assets	137,329	119,694
Property and equipment, net	1,377	984
Deferred tax assets, noncurrent	369
Restricted investments		364
Intangible assets, net		45,185
Goodwill	34,313	33,868	[2]
Other assets	683	749
Total assets	174,071	200,844
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	7,787	5,592
Accrued and other current liabilities	21,427	18,357	[2]
Deferred tax liabilities, current	153
Short-term borrowings on credit facilities	1,445	2,500
Total current liabilities	30,812	26,449
Contingent consideration, non-current		15,400
Deferred tax liabilities		8,407
Other long-term liabilities	237	469
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock; $0.001 par value; 100,000,000 shares authorized; 54,484,053 and 57,847,367 shares issued and outstanding at December 31, 2012 and 2011, respectively	54	58
Additional paid-in capital	274,387	266,913
Accumulated other comprehensive income	2,988	2,344
Accumulated deficit	(134,407)	(119,196)
Total stockholders' equity	143,022	150,119
Total liabilities and stockholders' equity	$ 174,071	$ 200,844

[1] Accounts receivable decreased $3.8 million and inventory increased $2.3 million related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.

[2] Goodwill increased $1.0 million and accrued and other current liabilities increased $1.0 million related to the Company recording a liability for expired product that existed at the time of the NovaMed acquisition, related to pre-acquisition Aggrastat product sales. Goodwill also increased $0.9 million related to the Company changing from the “sell-in” method to the “sell-through” method of revenue recognition for certain Pfizer products sold by the Company.